{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ANCA-Associated+Vasculitis+%28AAV%29", "query": { "condition": "ANCA-Associated Vasculitis (AAV)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ANCA-Associated+Vasculitis+%28AAV%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T00:40:40.681Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06308978", "title": "A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)", "Idiopathic Inflammatory Myositis (IIM)", "Systemic Sclerosis (SSc)", "Systemic Lupus Erythematosus (SLE)", "Lupus Nephritis" ], "interventions": [ { "name": "FT819", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "12 Years to 70 Years" }, "enrollment_count": 244, "start_date": "2024-03-28", "completion_date": "2042-09-30", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-05-22T00:40:40.681Z", "location_count": 13, "location_summary": "Fullerton, California • Irvine, California • Los Angeles, California + 10 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06308978" }, { "nct_id": "NCT05376319", "title": "PR3-AAV Resilient Remission or PRRR", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Granulomatosis With Polyangiitis", "Microscopic Polyangiitis", "ANCA Associated Vasculitis" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-06-30", "completion_date": "2024-05-07", "has_results": true, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-05-22T00:40:40.681Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Rochester, Minnesota • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05376319" }, { "nct_id": "NCT05732402", "title": "An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lupus Nephritis", "Immunoglobulin A Nephropathy", "Membranous Nephropathy", "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis" ], "interventions": [ { "name": "Povetacicept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alpine Immune Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2023-03-15", "completion_date": "2028-03-02", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-05-22T00:40:40.681Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Valencia", "state": "California" }, { "city": "Arvada", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05732402" }, { "nct_id": "NCT06072482", "title": "A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Antineutrophil Cytoplasmic Antibody-associated Vasculitis" ], "interventions": [ { "name": "Avacopan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 300, "start_date": "2024-02-07", "completion_date": "2036-12-31", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-05-22T00:40:40.681Z", "location_count": 58, "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Surprise, Arizona + 53 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Surprise", "state": "Arizona" }, { "city": "Searcy", "state": "Arkansas" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06072482" }, { "nct_id": "NCT06733935", "title": "A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Systemic Sclerosis", "Idiopathic Inflammatory Myopathies", "Antineutrophil Cytoplasmic Antibody-Associated Vasculitis" ], "interventions": [ { "name": "NKX019", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nkarta, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 144, "start_date": "2024-11-04", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-05-22T00:40:40.681Z", "location_count": 14, "location_summary": "Orange, California • Miami, Florida • Plantation, Florida + 11 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06733935" }, { "nct_id": "NCT01940094", "title": "The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Granulomatosis With Polyangiitis" ], "interventions": [ { "name": "5 mg Prednisone", "type": "DRUG" }, { "name": "0 mg Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2014-02", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-05-22T00:40:40.681Z", "location_count": 7, "location_summary": "Kansas City, Kansas • Boston, Massachusetts • Rochester, Minnesota + 4 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01940094" }, { "nct_id": "NCT06321601", "title": "Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Vasculitis" ], "interventions": [ { "name": "Avacopan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 20, "start_date": "2024-10-22", "completion_date": "2028-09-26", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-05-22T00:40:40.681Z", "location_count": 10, "location_summary": "Atlanta, Georgia • Indianapolis, Indiana • Minneapolis, Minnesota + 7 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Lake Success", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06321601" }, { "nct_id": "NCT01697267", "title": "Rituximab Vasculitis Maintenance Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis", "Microscopic Polyangiitis", "Wegener Granulomatosis" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Azathioprine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Cambridge University Hospitals NHS Foundation Trust", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 188, "start_date": "2013-04", "completion_date": "2019-11-21", "has_results": true, "last_update_posted_date": "2022-03-18", "last_synced_at": "2026-05-22T00:40:40.681Z", "location_count": 9, "location_summary": "Los Angeles, California • Ann Arbor, Michigan • Rochester, Minnesota + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01697267" }, { "nct_id": "NCT02108860", "title": "Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Granulomatosis With Polyangiitis (Wegener's)", "Granulomatosis With Polyangiitis", "Wegener's Granulomatosis", "ANCA-Associated Vasculitis" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 65, "start_date": "2015-04-25", "completion_date": "2023-12-20", "has_results": false, "last_update_posted_date": "2024-07-29", "last_synced_at": "2026-05-22T00:40:40.681Z", "location_count": 10, "location_summary": "Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02108860" }, { "nct_id": "NCT06375993", "title": "A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lupus Nephritis", "Autoimmune Diseases", "Systemic Sclerosis (SSc)", "Systemic Lupus Erythematosus (SLE)", "ANCA-Associated Vasculitis (AAV)", "Idiopathic Inflammatory Myopathies", "Stiff Person Syndrome" ], "interventions": [ { "name": "ADI-001", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adicet Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 180, "start_date": "2024-11-10", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-05-22T00:40:40.681Z", "location_count": 2, "location_summary": "Redwood City, California • Buffalo, New York", "locations": [ { "city": "Redwood City", "state": "California" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06375993" } ] }